Tag:
Nycomed
Latest Headlines
Latest Headlines
EC antitrust squad drops AZ-Nycomed probe
AstraZeneca ( $AZN ) and Nycomed are in the clear, at least as far as European regulators are concerned. The European Commission's antitrust squad has dropped an investigation of the two companies...
Wyeth puts $960M squeeze on Sun for Protonix launch
Sun Pharmaceuticals ' at-risk launch of generic Protonix may prove to have been risky indeed. Pfizer's ( $PFE ) Wyeth unit slapped the Indian drugmaker with a $960 million damages claim, alleging Sun's
Astellas scores highest in Japanese M&A bout
Japan’s biggest pharma players have been roaming the world in recent years in a restless search for new acquisitions. They've been looking for deals to put an extra oomph into their earnings.
Takeda abandons Euro rights to Durect's controlled-release pain drug
For the second time this year, Durect ($DRRX) faces a setback over its controlled-release anti-pain drug Posidur. The Cupertino, CA-based company disclosed that its European development and marketing
Takeda to ax 2,800 workers, consolidate R&D in global restructuring
Four months after closing its $14 billion Nycomed buyout, Japan's Takeda says it will take an ax to its R&D operations as it sheds 2,800 employees. Most of the layoffs will occur in Europe, with
Takeda's plate full with Nycomed integration
Takeda Pharmaceutical says its $13.7 billion acquisition of Nycomed is enough to digest for now. Despite the strong yen, which has been fueling Japanese companies' buyouts abroad, Takeda President
Nycomed snaps up Asian rights to Almirall med
Nycomed has hooked up with Spain's Almirall on a marketing deal. The Swiss drugmaker said it has licensed exclusive rights to Kestine, an antihistamine treatment for hay fever and hives, in China and
NICE asks for more data on Merck/Nycomed COPD drug
The U.K.'s cost-effectiveness watchdog has cast a skeptical eye on Merck ( $MRK ) and Nycomed's new lung drug Daxas. In draft guidance, the National Institute for Health and Clinical Excellence said
New Nycomed US chief aims to grow by M&A
Nycomed US hasn't even been born yet, and it's already promising big growth. Set to be spun off into an independent company once its Swiss parent Nycomed is bought out by Takeda Pharmaceutical,
Takeda snaps up Nycomed in $13.6B deal
Word on the street proved true today; Takeda Pharmaceutical announced it had agreed to buy Nycomed for almost $14 billion. The deal gives the Japanese drugmaker a couple of things it sorely needed: A
